DOR BioPharma, Inc announced today that it has received $1.5 million under a letter of intent with Sigma-Tau Pharmaceuticals, Inc, which grants Sigma-Tau an exclusive right to negotiate terms and conditions for a possible business transaction or strategic alliance regarding orBec (oral beclomethasone dipropionate or oral BDP) and potentially other DOR pipeline compounds until March 1, 2009.
The details can be read here.
No comments:
Post a Comment